
What We’re Reading: Senators Demand Answers on COVID-19 Relief; Limited Access to Miscarriage Drug; Pediatric Weight Loss Medication Trials
Three US senators asked the Social Security Administration to respond to a report saying it reduced or suspended benefits for those who received COVID-19 relief payments; mifepristone, a drug taken to help manage miscarriages, remains widely unavailable to patients experiencing pregnancy loss; pharmaceutical companies are beginning trials to get weight-loss shots approved for patients with obesity 6 years and older.
Senators Demand Answers From Social Security on COVID-19 Relief Clawbacks
Three US senators asked the Social Security Administration (SSA) to respond to a news report that said it reduced or suspended the benefits of people who received COVID-19 relief payments, according to . KFF Health News reported that the COVID-19 relief payments totaling as much as $3200 per person led the SSA to claw back other federal benefits, like monthly support payments for those impoverished, disabled, or aged 65 years or older. Also, the SSA sent notices to some people receiving Supplemental Security Income benefits who had more money than the $2000 asset limit due to COVID relief that alleged they were overpaid, asking them to repay the government; in some cases, SSA cut off benefit payments. The senators’ letter requested answers to a list of questions within 30 days.
Limited Access to Miscarriage Drug Nationwide
Mifepristone, a drug taken almost exclusively to induce abortions or manage miscarriages, is tightly regulated by the federal and state governments and remains widely unavailable to patients experiencing pregnancy loss, according to
Drug Companies Exploring Weight Loss Shots for Kids
Pharmaceutical companies are conducting trials in an attempt to get weight-loss shots approved for patients 6 years and older with obesity, according to
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.